新辅助放化疗对IIIA期患者未显示优于单纯化疗的生存优势
该研究基于美国国家癌症数据库,比较2006至2012年间接受新辅助放化疗(NCRT)与新辅助化疗(NCT)后行肺叶切除术的N2期且T1-T2的非小细胞肺癌患者。倾向性匹配分析显示,NCRT组病理完全缓解率和N0率更高,但30天和90天死亡率更高,且多因素分析中NCRT组死亡风险更高(HR 1.18),长期总生存无改善。
要点
- NCRT组病理完全缓解率14.2% vs NCT组4.0%,N0率45.2% vs 38.7%。
- NCT组30天死亡率1.3% vs NCRT组2.9%,90天死亡率2.9% vs 6.0%。
- 多因素分析NCRT组死亡风险更高(HR 1.18,95%CI 1.03-1.36)。
核心结论
- 在本队列中,新辅助放化疗与病理降期改善相关,但围手术期死亡率增加,长期总生存无改善。
- 对于无局部侵犯的较小肿瘤的IIIA期患者,作者认为单纯化疗可能是首选的新辅助治疗。
研究设计与样本
- 查询美国国家癌症数据库,纳入2006年至2012年间接受NCRT或NCT后行肺叶切除术的N2期且T1-T2的非小细胞肺癌患者,排除T3肿瘤。
- 共1936例符合标准,其中NCT组745例,NCRT组1191例;进行倾向性匹配分析,比较术后并发症、病理降期和长期生存。
主要发现
- NCRT组患者更年轻,更少在学术医疗中心治疗,更可能为腺癌。
- 倾向性匹配后,NCT组30天死亡率更低(1.3% vs 2.9%),90天死亡率更低(2.9% vs 6.0%),更可能接受微创切除(25.7% vs 14.1%)。
- NCRT组更可能达到病理完全缓解(14.2% vs 4.0%),切除时N0率更高(45.2% vs 38.7%)。
- 多因素分析中,NCRT组死亡风险高于NCT组(HR 1.18,95%CI 1.03-1.36)。
临床怎么用
- 对于IIIA期无局部侵犯的较小肿瘤患者,作者认为单纯化疗可能是首选的新辅助治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For operable patients with clinical stage IIIA non-small cell lung cancer, the optimum neoadjuvant treatment strategy remains unclear. Our aim was to compare perioperative and long-term outcomes for patients receiving neoadjuvant chemoradiotherapy (NCRT) versus neoadjuvant chemotherapy (NCT) alone. METHODS: We queried the National Cancer Database to identify all patients with N2 and either T1-T2 non-small cell lung cancer who received either NCRT or NCT followed by lobectomy between 2006 and 2012. Patients with T3 tumors were excluded. A propensity match analysis was performed incorporating preoperative variables, and the incidence of postoperative complications, pathologic downstaging, and long-term survival were compared. RESULTS: In all, 1,936 patients met criteria, 745 NCT and 1,191 NCRT. The NCRT patients were younger, less likely to be treated at an academic medical center, and more likely to have adenocarcinoma. After propensity matching, patients in the NCT group showed lower 30-day mortality (1.3% versus 2.9%) and 90-day mortality (2.9% versus 6.0%), and were more likely to undergo a minimally invasive resection (25.7% versus 14.1%). The NCRT patients were more likely to have a pathologic complete response (14.2% versus 4.0%) and to be N0 at the time of resection (45.2% versus 38.7%). In the multivariable analysis, NCRT patients were at a greater risk of mortality than NCT patients (hazard ratio 1.18, 95% confidence interval: 1.03 to 1.36). CONCLUSIONS: In our cohort, combined neoadjuvant chemotherapy and radiation therapy was associated with improved pathologic downstaging but showed increased perioperative mortality with no improvement in long-term overall survival. For stage IIIA patients with smaller tumors without local invasion, chemotherapy alone may be the preferred neoadjuvant treatment.
引用
- Krantz SB, Mitzman B, Lutfi W, et al. Neoadjuvant Chemoradiation Shows No Survival Advantage to Chemotherapy Alone in Stage IIIA Patients. Ann Thorac Surg. 2018. PMID: 29453000. doi:10.1016/j.athoracsur.2017.10.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。